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July 3, 2007:79–81elative risk for moderate to severe diastolic dysfunction versus
ild dysfunction and normal function is 3.8 for CV1 and 3.9 for
V2. Mild diastolic dysfunction in this subset carries a similar
rognosis as in the full study (7% vs. 6%), whereas the normal
roup has a nonsignificantly better prognosis (0% vs. 4%).
Thus, using a non–age-adjusted Doppler-echocardiographic
lassification of diastolic function, we can conclude that normal
iastolic function and mild diastolic dysfunction are seen in 60% of
he patients, and the relationship is graded between severity of
iastolic dysfunction and outcome, with a 4-fold risk increase for
oderate to severe diastolic dysfunction compared to normal
iastolic function and mild diastolic dysfunction and 2-fold when
omparing moderate and severe to mild dysfunction. The recalcu-
ations do not suggest a different picture from the previous primary
nalysis.
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atent Foramen Ovale
nd Stroke Risk:
he Devil Is in the Detail
he risk of stroke due to a patent foramen ovale (PFO) is real.
ase reports document venous thrombi slipping through a fora-
Table 1
Diastolic Function Groups in CHARMES a
Cardiovascular Events in CHARMES Subs
Diastolic Function
CHARMES
(n  293)
C
Normal 33% (n 98)
Mild dysfunction 22% (n 65)
Moderate dysfunction 37% (n 109)
Severe dysfunction 7% (n 21)
See text for explanations of end points CV1 and CV2.en ovale to the left atrium and causing a stroke (1). The absolute
5isk for ischemic strokes in the presence of a PFO is unknown. The
eport of Di Tullio et al. (2) in a recent issue of the Journal may not
hed more light on this question, because some “minor” details
ould end up seriously biasing their results.
As the investigators point out in their discussion, the prevalence
f a PFO in the general population is close to one-quarter (3). The
revalence of a PFO in the current study is 15%. The most likely
eason for this low PFO prevalence is underdiagnosis of interatrial
hunts by transthoracic echocardiography (4). Otherwise, the
esearchers have to argue for a lower PFO prevalence in citizens
rom northern Manhattan compared to other cities of the U.S.
issing 4 of 10 PFOs would lower the hazard ratio (HR) for
troke in the PFO group compared to the non-PFO group,
ecause these nondiagnosed shunts may increase the risk for stroke
n the latter group. The results of the Cox regression models as
resented would underestimate the actual hazard. In addition to
he problem of underdiagnosis, a question arises regarding the
atients studied. The mean age of patients participating in this
roject was 68 to 69 years. The association of a PFO and stroke has
een demonstrated for patients 55 years (5) and is probably
eaker in the elderly with competing conventional cardiovascular
isk factors as hypertension, diabetes, and dyslipidemia.
Last but not least, Di Tullio et al. (2) should provide not only
he HR for a stroke in the setting of a PFO, but also the
orresponding HRs for other cardiovascular risk factors they
orrected for.
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bset:
Diastolic Function Group
ES Subset
181) CV1 CV2
(n 56) 0% 0%
(n 53) 7% (n 4) 11% (n 6)
(n 55) 15% (n 8) 22% (n 12)
(n 17) 12% (n 2) 18% (n 3)nd Su
et by
HARM
(n 
31%
29%
31%
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